Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Marqibo ® (vincristine sulfate liposomes injection; VSLI) In the Treatment of Adult Patients with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and RALLY Studies

Susan O'Brien, M.D., Deborah A Thomas, M.D., Leonard T Heffner, M.D., Wendy Stock, M.D., Gerald L. Messerschmidt, M.D., Anne Hagey, M.D., Steven R. Deitcher, M.D., Hagop Kantarjian, M.D.

Blood (2010) 116 (21): 2143.

https://doi.org/10.1182/blood.V116.21.2143.2143

Published: 2010

Journal Articles

Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs).

Sameer A Parikh, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Tapan Kadia, MD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Jenny Feliu, RN, Stefan Faderl, MD

Blood (2009) 114 (22): 2058.

https://doi.org/10.1182/blood.V114.22.2058.2058

Published: 2009

Journal Articles

The Outcome of Patients (pts) with Acute Promyelocytic Leukemia (APL) Who Fail Both All– Trans -retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

Ravin Jain Garg, M.D., Hagop Kantarjian, M.D., Meetu Agrawal, M.B.B.S., Farhad Ravandi, MD, Gautam Borthakur, M.D., Steven M. Kornblau, MD, Alessandra Ferrajoli, M.D., Guillermo Garcia-Manero, MD, Susan O'Brien, M.D., Jorge Cortes, MD

Blood (2009) 114 (22): 4143.

https://doi.org/10.1182/blood.V114.22.4143.4143

Published: 2009

Journal Articles

Plasma Circulating Caspase-3 Index as a Biomarker in Patients with Chronic Lymphocytic Leukemia.

Jean-Marie Bruey, Zeev Estrov, MD, Hagop Kantarjian, M.D., Susan O'Brien, M.D., Michael Keating, MD, William Wierda, Maher Albitar, M.D.

Blood (2009) 114 (22): 4381.

https://doi.org/10.1182/blood.V114.22.4381.4381

Published: 2009

Journal Articles

Experience with the Combination of a Hypomethylating Agent and Valproic Acid in Pediatric Acute Myelogenous Leukemia

Michael Rytting, M.D., Patrick Zweidler-McKay, M.D., Ph.D., Yang Hui, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D.

Blood (2008) 112 (11): 4036.

https://doi.org/10.1182/blood.V112.11.4036.4036

Published: 2008

Journal Articles

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Weigang Tong, M.D., Ph.D., Hagop Kantarjian, M.D., Susan O’Brien, M.D., Stefan Faderl, MD, Farhad Ravandi, MBBS, William G Wierda, M.D., Ph.D., Steven Kornblau, M.D., Gautam Borthakur, M.D., Guillermo Garcia-Manero, M.D., Elizabeth Burton, Mary Beth Rios, Jorge Cortes, M.D.

Blood (2008) 112 (11): 2126.

https://doi.org/10.1182/blood.V112.11.2126.2126

Published: 2008

Journal Articles

Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1 T315I Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Nicholas Donato, Ph.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 1952.

https://doi.org/10.1182/blood.V110.11.1952.1952

Published: 2007

Journal Articles

Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Deborah Thomas, M.D., Charles Koller, M.D., Jenny Shan, Jorge Cortes, M.D.

Blood (2007) 110 (11): 1955.

https://doi.org/10.1182/blood.V110.11.1955.1955

Published: 2007

Journal Articles

Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.

Wanlong Ma, Xi Zhang, Iman Jilani, Ph.D., Zhong Zhang, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Francis Giles, M.D., Susan O’Brien, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2554.

https://doi.org/10.1182/blood.V110.11.2554.2554

Published: 2007

Journal Articles

Phase II Study of Dasatinib (SPRYCEL™) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.

Srdan Verstovsek, MD, PhD, Tefferi Ayalew, M.D., Cortes Jorge, M.D., Susan O’Brien, M.D., Guillermo Garcia-Manero, M.D., Animesh Pardanani, M.D., Cem Akin, M.D., Stefan Faderl, M.D., Deborah Thomas, M.D., Hagop Kantarjian, M.D.

Blood (2007) 110 (11): 3551.

https://doi.org/10.1182/blood.V110.11.3551.3551

Published: 2007

Journal Articles

Mutations within BCR-ABL1 295–312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia (CML) Resistant to Imatinib.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Jorge Cortes, M.D., Nicholas Donato, Ph.D.

Blood (2007) 110 (11): 1936.

https://doi.org/10.1182/blood.V110.11.1936.1936

Published: 2007

Journal Articles

Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Nick Donato, Ph.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 1938.

https://doi.org/10.1182/blood.V110.11.1938.1938

Published: 2007

Journal Articles

T Cell Blast Phase (T-BP) of Chronic Myelogenous Leuikemia (CML).

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 4560.

https://doi.org/10.1182/blood.V110.11.4560.4560

Published: 2007

Journal Articles

Basophilic Blast Phase (B-BP) of Chronic Myelogenous Leukemia (CML).

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 4562.

https://doi.org/10.1182/blood.V110.11.4562.4562

Published: 2007

Journal Articles

Megakaryocytic Blast Phase (M-BP) of Chronic Myelogenous Leukemia (CML).

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 4563.

https://doi.org/10.1182/blood.V110.11.4563.4563

Published: 2007

Journal Articles

Higher Sensitivity and Detection of Homozygous/Hemizygous State of JAK2 Mutation Using Plasma.

Wanlong Ma, Xi Zhang, Weimin Sun, Ph.D, Joyce Schwartz, M.D., Arlene Buller, Ph.D., Iman Jilani, Ph.D., Hagop Kantarjian, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 4663.

https://doi.org/10.1182/blood.V110.11.4663.4663

Published: 2007

Journal Articles

Activity of Circulating Proteasomes Correlates with Clinical Behavior in Patients with Chronic Myeloid Leukemia.

Wanlong Ma, Hagop Kantarjian, M.D., Amber Donahue, Ph.D., Xi Zhang, Susan O’Brien, M.D., Iman Jilani, Ph.D., Elihu Estey, M.D., Zeev Estrov, M.D., Jorge Cortes, M.D., Michael Keating, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 4546.

https://doi.org/10.1182/blood.V110.11.4546.4546

Published: 2007

Journal Articles

SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia.

Jeffrey Lancet, MD, Hagop Kantarjian, M.D., Farhad Ravandi, M.D., Sem Bastien, R.N., Katrina Alino, R.N., Glenn Michelson, M.D., Judith Karp, M.D.

Blood (2007) 110 (11): 442.

https://doi.org/10.1182/blood.V110.11.442.442

Published: 2007

Journal Articles

Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Farhad Ravandi, M.D., Jan Burger, M.D., Gautam Borthakur, M.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 2958.

https://doi.org/10.1182/blood.V110.11.2958.2958

Published: 2007

Journal Articles

Molecular Basis Explanation of Imatinib Resistance of Bcr-Abl Due to T315I and P-Loop Mutations from Molecular Dynamics Simulations.

Tai-Sung Lee, Steven Potts, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2917.

https://doi.org/10.1182/blood.V110.11.2917.2917

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Marqibo ® (vincristine sulfate liposomes injection; VSLI) In the Treatment of Adult Patients with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and RALLY Studies

Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs).

The Outcome of Patients (pts) with Acute Promyelocytic Leukemia (APL) Who Fail Both All– Trans -retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

Plasma Circulating Caspase-3 Index as a Biomarker in Patients with Chronic Lymphocytic Leukemia.

Experience with the Combination of a Hypomethylating Agent and Valproic Acid in Pediatric Acute Myelogenous Leukemia

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1 T315I Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain.

Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib.

Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.

Phase II Study of Dasatinib (SPRYCEL™) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.

Mutations within BCR-ABL1 295–312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia (CML) Resistant to Imatinib.

Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.

T Cell Blast Phase (T-BP) of Chronic Myelogenous Leuikemia (CML).

Basophilic Blast Phase (B-BP) of Chronic Myelogenous Leukemia (CML).

Megakaryocytic Blast Phase (M-BP) of Chronic Myelogenous Leukemia (CML).

Higher Sensitivity and Detection of Homozygous/Hemizygous State of JAK2 Mutation Using Plasma.

Activity of Circulating Proteasomes Correlates with Clinical Behavior in Patients with Chronic Myeloid Leukemia.

SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia.

Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy.

Molecular Basis Explanation of Imatinib Resistance of Bcr-Abl Due to T315I and P-Loop Mutations from Molecular Dynamics Simulations.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only